IceCure Medical Ltd. (ICCM)
Company Description
IceCure Medical is a commercial stage medical device company focusing on the research, development and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors.
In the United States our products are approved as a “single family” known as the “IceCure Family,” which includes the IceSense3, ProSense, and MultiSense (which has not been commercialized) cryoablation systems.
Cryoablation is the process by which benign and malignant tumors are ablated (destroyed) through freezing such tumors while in a patient’s body. Our proprietary cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications.
In our continued efforts aimed at improving our core technology, we are currently focusing on developing our next generation MultiSense system, which we intend to commercialize subject to regulatory approvals.
We are also in the process of developing our next generation single probe system. While these next generation systems are still in various research and development stages, we expect them to be more efficient and user friendly.
| Country | Israel |
| Founded | 2006 |
| Industry | Medical Devices |
| Sector | Health Care |
| Employees | 48 |
| CEO | Eyal Shamir |
Contact Details
Address:
7 Ha’Eshel St., PO Box 3163 Caesarea 3079504 Israel | |
| Phone | 972 4 623 0333 |
| Website | icecure-medical.com |
Stock Details
| Ticker Symbol | ICCM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| CIK Code | 1584371 |
| ISIN Number | IL0011224156 |
Key Executives
| Name | Position |
|---|---|
| Eyal Shamir | Chief Executive Officer and Director |
| Ronen Tsimerman CPA | Chief Financial Officer and Chief Operating Officer |
| Tlalit Bussi Tel-Tzure | Vice President of Business Development and Global Marketing |
| Merav Nir Dotan | Vice President of Human Resources |
| Naum Muchnik | Vice President of Research, Development and Engineering |
| Shay Levav | Vice President of Regulatory and Quality Assurance and Clinical Applications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 13, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| Jun 9, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| Jun 9, 2022 | EFFECT | Notice of Effectiveness |
| Jun 3, 2022 | POS AM | Post-Effective amendments for registration statement |
| May 18, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| Apr 29, 2022 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 5, 2022 | EFFECT | Notice of Effectiveness |
| Apr 4, 2022 | POS AM | Post-Effective amendments for registration statement |
| Apr 1, 2022 | POS AM | Post-Effective amendments for registration statement |
| Apr 1, 2022 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] |